446,866 Axon Enterprise, Inc $AXON Shares Purchased by Candriam S.C.A.

Candriam S.C.A. raised its position in Axon Enterprise, Inc (NASDAQ:AXON) by 6,980.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 453,268 shares of the biotechnology company’s stock after purchasing an additional 446,866 shares during the period. Axon Enterprise comprises about 0.9% of Candriam S.C.A.’s investment portfolio, making the stock its 20th largest position. Candriam S.C.A. owned about 0.56% of Axon Enterprise worth $191,515,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. M & L Capital Management Ltd purchased a new stake in shares of Axon Enterprise during the third quarter worth about $30,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Axon Enterprise in the second quarter valued at approximately $31,000. Wealth Enhancement Trust Services Inc. acquired a new position in shares of Axon Enterprise in the third quarter valued at approximately $33,000. Putney Financial Group LLC acquired a new position in shares of Axon Enterprise in the third quarter valued at approximately $36,000. Finally, Washington Trust Advisors Inc. lifted its stake in shares of Axon Enterprise by 1,300.0% during the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 65 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AXON. Needham & Company LLC decreased their target price on shares of Axon Enterprise from $750.00 to $500.00 and set a “buy” rating on the stock in a research report on Friday. Northland Securities set a $540.00 target price on shares of Axon Enterprise in a research note on Friday. The Goldman Sachs Group cut their price target on Axon Enterprise from $715.00 to $675.00 and set a “buy” rating for the company in a report on Monday, September 21st. Citigroup reissued a “market outperform” rating on shares of Axon Enterprise in a research note on Monday, November 2nd. Finally, Raymond James Financial set a $675.00 price objective on Axon Enterprise in a report on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $631.35.

Axon Enterprise Stock Down 18.2%

AXON opened at $313.00 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The stock has a market capitalization of $25.43 billion, a price-to-earnings ratio of 100.32, a price-to-earnings-growth ratio of 5.95 and a beta of 1.48. The business has a 50-day moving average of $441.53 and a two-hundred day moving average of $475.20. Axon Enterprise, Inc has a 12 month low of $307.00 and a 12 month high of $665.07.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a net margin of 7.56% and a return on equity of 3.95%. The company’s revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.17 EPS. On average, research analysts expect that Axon Enterprise, Inc will post 2.10 earnings per share for the current year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the transaction, the president owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the transaction, the insider directly owned 97,761 shares in the company, valued at approximately $61,266,818.70. This represents a 8.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 37,397 shares of company stock valued at $21,234,034 over the last three months. Insiders own 4.20% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.